We recommend you to use RedHill Biopharma fundamental analysis to see if markets are presently mispricing the firm. In other words this interface allows you to confirm available drivers of RedHill Biopharma as well as the relationship between them. . We found twenty-six available financial ratios for RedHill Biopharma which can be compared to its competitors. To make sure the equity is not overpriced, please check all RedHill Biopharma fundamentals including its Shares Outstanding, Revenue, EBITDA, as well as the relationship between Price to Sales and Gross Profit . Use RedHill Biopharma to enhance returns of your portfolios. The stock experiences very speculative upward sentiment. . Check odds of RedHill Biopharma to be traded at S407.25 in 30 days.
RedHill Biopharma Company Summary
RedHill Biopharma competes with Kamada Ltd, Compugen Ltd, BioTime, Clal Biotechnology, and Pluristem Therapeutics. RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel. RedHill Biopharma operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 75 people.
RedHill Biopharma Cash Flow from Operations vs Number of Employees